Atlas Genetics - Annual Summary 2014 - Setting the new standard in decentralised molecular diagnostics
Print 02 May 2015
Setting the new standard in decentralised molecular diagnostics
Bath, UK, 1 May 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), developer of innovative, ultra-rapid diagnostics to enable a ‘test and treat’ solution to infectious diseases, today announces its Annual Summary for 2014.
- Completion of the io® Cartridge development and establishment of pilot manufacturing capability at Bespak
- CE-marking of io® reader
- Closed final tranche of £16.9m Series B financing and completed £12.7m Series C funding, including new investment from RMI Partners
- Achieved full ISO 13485 accreditation
- R&D cartridge assembly facility commissioned at Atlas Genetics
- Signed first Distribution Agreement with NovaMedica for Russia & CIS
- Atlas Genetics wins Best for Innovation, British Private Equity and Venture Capital Association (BVCA) Regional Management Awards
John Clarkson, CEO of Atlas Genetics, said: “2014 has been a year of very significant achievement for Atlas Genetics. Our io® system is now close to being finalised and approved for sale later this year. The io® Reader is in production and we have received the first 65 instruments from our manufacturing partner LRE (part of the Esterline Group). In June, we announced that we had completed development of the Cartridge and had established a pilot manufacturing capability at Bespak ready for full commercial scale up following launch. With funding secure and our first distribution agreement signed, we believe that Atlas Genetics is now well placed to capture a new POC market to address the increasingly unmet need in the treatment and control of infectious diseases.
“As a credit to all our staff, Atlas Genetics was awarded the prestigious Best for Innovation award from the British Private Equity and Venture Capital Association (BVCA) Management Awards and I would like to thank them for their continuous commitment and hard work.”
For the full Annual Summary, please go to: www.atlasgenetics.com
Download
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.